SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
38:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
18.   Sandler  A, :@0.084848:0.094740:0.219254:0.094740:0.219254:0.080735:0.084848:0.080735:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.011682:0.010434:0.011716:0.003421:0.011118:0.005148:0.004738:0.009151:0.012657:0.004738:0.004738
et al:@0.228405:0.094740:0.274313:0.094740:0.274313:0.080735:0.228405:0.080735:0.011118:0.005798:0.013889:0.011682:0.003421
. Paclitaxel-carboplatin :@0.274313:0.094740:0.480489:0.094740:0.480489:0.080735:0.274313:0.080735:0.004738:0.013889:0.010126:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.005679:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738
alone or with bevacizumab for non-small-:@0.121195:0.107428:0.475753:0.107428:0.475753:0.093423:0.121195:0.093423:0.011682:0.003421:0.011203:0.010434:0.011118:0.006927:0.011203:0.005140:0.006927:0.014214:0.003421:0.005798:0.010434:0.006927:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.006938:0.005371:0.011203:0.005148:0.006927:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679
cell lung cancer. :@0.121195:0.120116:0.278837:0.120116:0.278837:0.106111:0.121195:0.106111:0.011067:0.011118:0.003421:0.003421:0.012059:0.003421:0.010399:0.010434:0.011511:0.012059:0.011067:0.011682:0.010434:0.011067:0.011118:0.003891:0.004738:0.004738
N Engl J Med:@0.286158:0.120116:0.416322:0.120116:0.416322:0.106111:0.286158:0.106111:0.012657:0.012059:0.009168:0.010434:0.011511:0.003421:0.012059:0.008244:0.012059:0.015719:0.011118:0.011716
. 2006; :@0.416322:0.120116:0.480498:0.120116:0.480498:0.106111:0.416322:0.106111:0.004738:0.012059:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
355:2542-2550.:@0.121195:0.132805:0.240584:0.132805:0.240584:0.118799:0.121195:0.118799:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
19.   Peters S, Kerr KM, Stahel R. PD-1 blockade :@0.084848:0.145493:0.480505:0.145493:0.480505:0.131487:0.084848:0.131487:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011118:0.005798:0.011118:0.005148:0.006636:0.006382:0.008518:0.004738:0.006397:0.010109:0.011118:0.005140:0.005148:0.006388:0.010109:0.015719:0.004738:0.006385:0.008518:0.005798:0.011682:0.010434:0.011118:0.003421:0.006397:0.010382:0.004738:0.006388:0.010126:0.012726:0.005679:0.009476:0.006397:0.011665:0.003421:0.011203:0.011067:0.008586:0.011682:0.011716:0.011118:0.004738
in advanced NSCLC: a focus on pembroli-:@0.121195:0.158181:0.475767:0.158181:0.475767:0.144176:0.121195:0.144176:0.003421:0.010434:0.005490:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005490:0.012657:0.008518:0.013906:0.007902:0.013906:0.004738:0.005477:0.011682:0.005490:0.005371:0.011203:0.011067:0.010399:0.006636:0.005480:0.011203:0.010434:0.005479:0.011665:0.011118:0.016044:0.011665:0.005080:0.011203:0.003421:0.003421:0.005679
zumab. :@0.121195:0.170869:0.187731:0.170869:0.187731:0.156864:0.121195:0.156864:0.007269:0.010399:0.016044:0.011682:0.011665:0.004738:0.004738
Cancer Treatment Reviews:@0.191990:0.170869:0.424118:0.170869:0.424118:0.156864:0.191990:0.156864:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.008997:0.007286:0.005148:0.011118:0.011682:0.005798:0.016044:0.011106:0.010434:0.005798:0.008997:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636
. 2018 :@0.424118:0.170869:0.480494:0.170869:0.480494:0.156864:0.424118:0.156864:0.004738:0.008997:0.009476:0.009476:0.009476:0.009476:0.004738
January;62:39-49.:@0.121195:0.183557:0.264701:0.183557:0.264701:0.169552:0.121195:0.169552:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
20.   Hofmann  L, :@0.084848:0.196246:0.222822:0.196246:0.222822:0.182240:0.084848:0.182240:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.011682:0.011203:0.005371:0.016044:0.011682:0.010434:0.010434:0.004738:0.002661:0.007902:0.004738:0.004738
et al:@0.225480:0.196246:0.264906:0.196246:0.264906:0.182240:0.225480:0.182240:0.011118:0.005798:0.007406:0.011682:0.003421
. Cutaneous, gastrointes-:@0.264906:0.196246:0.475755:0.196246:0.475755:0.182240:0.264906:0.182240:0.004738:0.007406:0.013906:0.010399:0.005798:0.011682:0.010434:0.011118:0.011203:0.010387:0.006636:0.004738:0.007406:0.011511:0.011682:0.006636:0.005798:0.005078:0.011203:0.003421:0.010434:0.005798:0.011118:0.006636:0.005679
tinal, hepatic, endocrine,  and renal side-:@0.121195:0.208934:0.475755:0.208934:0.475755:0.194929:0.121195:0.194929:0.005798:0.003421:0.010434:0.011682:0.003421:0.004738:0.008125:0.010434:0.011118:0.011665:0.011682:0.005798:0.003421:0.011067:0.004738:0.008125:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.004738:0.003376:0.011682:0.010434:0.011716:0.008125:0.005077:0.011118:0.010434:0.011682:0.003421:0.008125:0.006636:0.003421:0.011716:0.011118:0.005679
effects of anti-PD-1 therapy. :@0.121195:0.221622:0.385728:0.221622:0.385728:0.207617:0.121195:0.207617:0.011118:0.005419:0.005371:0.011118:0.011067:0.005798:0.006636:0.013974:0.011203:0.005371:0.013974:0.011682:0.010434:0.005798:0.003421:0.005679:0.010126:0.012726:0.005679:0.009476:0.013974:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
European :@0.394950:0.221622:0.480506:0.221622:0.480506:0.207617:0.394950:0.207617:0.009168:0.010399:0.005148:0.011203:0.011665:0.011118:0.011682:0.010434:0.004738
Journal of Cancer:@0.121195:0.235933:0.271132:0.235933:0.271132:0.221928:0.121195:0.221928:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738:0.011203:0.005371:0.004738:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. 2016;60:190-209.:@0.271115:0.235933:0.414193:0.235933:0.414193:0.221928:0.271115:0.221928:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
21.   Hanna N, :@0.084848:0.250244:0.206033:0.250244:0.206033:0.236239:0.084848:0.236239:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.011682:0.011682:0.010434:0.010434:0.011682:0.006790:0.012657:0.004738:0.004738
et al.:@0.208085:0.250244:0.251633:0.250244:0.251633:0.236239:0.208085:0.236239:0.011118:0.005798:0.006790:0.011682:0.003421:0.004738
 Randomised phase III trial :@0.251633:0.250244:0.480489:0.250244:0.480489:0.236239:0.251633:0.236239:0.006790:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.006790:0.011665:0.010434:0.011682:0.006636:0.011118:0.006790:0.003866:0.003866:0.003866:0.006790:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738
of pemetrexed:@0.560589:0.094716:0.684112:0.094716:0.684112:0.080711:0.560589:0.080711:0.011203:0.005371:0.003968:0.011665:0.011118:0.016044:0.011118:0.005798:0.005075:0.011118:0.008210:0.011118:0.011716
 versus:@0.684112:0.094716:0.737494:0.094716:0.737494:0.080711:0.684112:0.080711:0.003968:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 docetaxel in patients :@0.737494:0.094716:0.919878:0.094716:0.919878:0.080711:0.737494:0.080711:0.003968:0.011716:0.011203:0.011067:0.011118:0.005798:0.011682:0.008210:0.011118:0.003421:0.003968:0.003421:0.010434:0.003968:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738
with non-small-cell lung cancer previously :@0.560589:0.108851:0.919878:0.108851:0.919878:0.094846:0.560589:0.094846:0.014214:0.003421:0.005798:0.010434:0.007286:0.010434:0.011203:0.010425:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679:0.011078:0.011118:0.003421:0.003421:0.007297:0.003421:0.010399:0.010434:0.011511:0.007286:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.007286:0.011665:0.005078:0.011118:0.009476:0.003421:0.011203:0.010399:0.006636:0.003421:0.009168:0.004738
treated with chemotherapy. :@0.560589:0.122986:0.804569:0.122986:0.804569:0.108980:0.560589:0.108980:0.005798:0.005075:0.011118:0.011682:0.005798:0.011118:0.011716:0.006725:0.014214:0.003421:0.005798:0.010434:0.006727:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
J Clin Oncol.:@0.806550:0.122986:0.915159:0.122986:0.915159:0.108980:0.806550:0.108980:0.008244:0.006727:0.013906:0.003421:0.003421:0.010434:0.006731:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.915159:0.122986:0.919897:0.122986:0.919897:0.108980:0.915159:0.108980:0.004738
2004; 22:1589-1597.:@0.560589:0.137120:0.717881:0.137120:0.717881:0.123115:0.560589:0.123115:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
22.   Shepherd  FA,:@0.524242:0.151255:0.674289:0.151255:0.674289:0.137250:0.524242:0.137250:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.010434:0.011118:0.011665:0.010434:0.011118:0.005039:0.011716:0.004738:0.004259:0.007266:0.012657:0.004738
 et al.:@0.674289:0.151255:0.729040:0.151255:0.729040:0.137250:0.674289:0.137250:0.008997:0.011118:0.005798:0.008997:0.011682:0.003421:0.004738
 Erlotinib in previously :@0.729040:0.151255:0.919890:0.151255:0.919890:0.137250:0.729040:0.137250:0.008997:0.009168:0.005148:0.003421:0.011203:0.005798:0.003421:0.010434:0.003421:0.011665:0.008997:0.003421:0.010434:0.008997:0.011665:0.005080:0.011118:0.009476:0.003421:0.011203:0.010399:0.006636:0.003421:0.009168:0.004738
treated non-small-cell lung cancer. :@0.560589:0.165389:0.860045:0.165389:0.860045:0.151384:0.560589:0.151384:0.005798:0.005075:0.011118:0.011682:0.005798:0.011118:0.011716:0.006329:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.006339:0.003421:0.010399:0.010434:0.011511:0.006329:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
N Engl :@0.861636:0.165389:0.919893:0.165389:0.919893:0.151384:0.861636:0.151384:0.012657:0.006329:0.009168:0.010434:0.011511:0.003421:0.004738
J Med:@0.560589:0.179524:0.612124:0.179524:0.612124:0.165519:0.560589:0.165519:0.008244:0.004738:0.015719:0.011118:0.011716
. 2005;353:123-132.:@0.612124:0.179524:0.764678:0.179524:0.764678:0.165519:0.612124:0.165519:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
23.   Waqar SN, Morgensztern D. Treatment ad-:@0.524242:0.193659:0.915142:0.193659:0.915142:0.179653:0.524242:0.179653:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015568:0.011682:0.011665:0.011682:0.005148:0.006123:0.008518:0.012657:0.004738:0.006123:0.015719:0.011203:0.005159:0.011511:0.011118:0.010434:0.006636:0.007269:0.005798:0.011118:0.005492:0.010434:0.006123:0.012726:0.004738:0.006123:0.006773:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.006123:0.011682:0.011716:0.005679
vances in small cell lung  cancer  (SCLC) :@0.560589:0.207793:0.919893:0.207793:0.919893:0.193788:0.560589:0.193788:0.009476:0.011682:0.010434:0.011067:0.011118:0.006636:0.009493:0.003421:0.010434:0.009493:0.006636:0.016044:0.011682:0.003421:0.003421:0.009493:0.011067:0.011118:0.003421:0.003421:0.009493:0.003421:0.010399:0.010434:0.011511:0.004738:0.004745:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004741:0.006312:0.008518:0.013906:0.007902:0.013906:0.006312:0.004738
Pharmacology & Therapeutics:@0.560589:0.221928:0.826904:0.221928:0.826904:0.207923:0.560589:0.207923:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.012452:0.012948:0.012452:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.006636
. St Louis: :@0.826904:0.221928:0.919900:0.221928:0.919900:0.207923:0.826904:0.207923:0.004738:0.012452:0.008518:0.005798:0.012452:0.007902:0.011203:0.010399:0.003421:0.006636:0.004738:0.004738
Washington University School of Medicine; :@0.560589:0.236063:0.919892:0.236063:0.919892:0.222057:0.560589:0.222057:0.015568:0.011682:0.006636:0.010434:0.003421:0.010434:0.011511:0.005798:0.011203:0.010434:0.006607:0.011203:0.010434:0.003421:0.009476:0.011118:0.005148:0.006636:0.003421:0.005798:0.009168:0.006619:0.008518:0.011067:0.010434:0.011203:0.011203:0.003421:0.006611:0.011203:0.005371:0.006611:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738:0.004738
2017.:@0.560589:0.250197:0.603230:0.250197:0.603230:0.236192:0.560589:0.236192:0.009476:0.009476:0.009476:0.009476:0.004738